Visilizumab is an IgG2 humanized monoclonal antibody (mAb) characterized by non-FcγR
binding and specific to the CD3 antigen, expressed on more than 95% of circulating resting …

Pretargeted radioimmunotherapy (RIT) using streptavidin (sAv)-conjugated antibodies
before radiolabeled-biotin is a promising approach to improve absorbed dose ratios and …

Purpose The rationale of the present study was to radiolabel rituximab with 99m-technetium
and to image B lymphocytes infiltration in the affected tissues of patients with chronic …

Purpose It is known that major histocompatibility complex class II protein HLA-DR is highly
expressed in B-cell lymphomas and in a variety of autoimmune and inflammatory diseases …

Myeloablative radioimmunotherapy using 131I-tositumomab (anti-CD20) monoclonal
antibodies is an effective therapy for B-cell non-Hodgkin's lymphoma. The amount of …

Radioimmunotherapy (RIT) using 131I-tositumomab has been used successfully to treat
relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Our approach to treatment …

We determined whether therapeutic responses using a bispecific antibody that pretargeted
90Y-hapten-peptide radioimmunotherapy or a directly radiolabeled, humanized, 90Y-anti …

B cells arise from stem cells precursor and develop through a tightly regulated and selective
process that lead to the generation of different B cell populations such as transitional …

We studied the feasibility of using the α-emitting 213Bi-anti-CD20 therapy with direct
bioluminescent tracking of micrometastatic human B-cell lymphoma in a SCID mouse model …

Objective This study was performed to explore the possibility of using 99m Tc-rituximab as
an imaging agent to assess expression of CD20 antigen in patients with B-cell non …